Abstract
Immune checkpoint blockades were reported to result in clinical responses in inoperable and metastatic cutaneous squamous cell carcinoma (cSCC). This report describes an 87-year-old woman with recurrent cSCC that was initially responsive to cetuximab (the monoclonal antibody against epithelial growth factor receptor) but eventually became refractory to cetuximab and multiple subsequent salvage chemotherapy regimens. Next-generation sequencing of the tumor discovered three single-nucleotide mutations in TP53, copy number amplification in Src, and a heterozygous deletion in BRCA2. Because of the high mutation burden of her neoplasm (35.2 mutations per megabase), we treated her with a programmed death-1 (PD-1) checkpoint inhibitor, pembrolizumab, for 10 months. The tumor regressed 3 months later and complete pathological remission was achieved 10 months after starting treatment. As of writing, the patient has been disease free for 17 months after discontinuing treatment. This is the first reported case of heterozygous deletion of BRCA2 in cSCC. The high mutation burden and BRCA2 mutation might explain why this tumor was highly sensitive to anti-PD-1 treatment.
References
Apr 25, 2003·The New England Journal of Medicine·Sylvie EuvrardAlain Claudy
Nov 26, 2009·Cancer Research·Liang ZhaoJohn T Seykora
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eve MaubecMarie-Françoise Avril
Apr 10, 2012·Seminars in Oncology·Ronald C DeConti
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Aug 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M C FooteS V Porceddu
Oct 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Curtis R PickeringMitchell J Frederick
Jan 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yvonne Y LiPeter S Hammerman
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Jul 30, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander StratigosUNKNOWN European Organization for Research and Treatment of Cancer (EORTC)
Aug 19, 2015·The Journal of Dermatology·Pai-Shan ChengFeng-Jie Lai
Oct 20, 2015·Cancer·Rami N Al-RohilJeffrey S Ross
Mar 22, 2016·Cell·Willy HugoRoger S Lo
Mar 3, 2017·Science Translational Medicine·Whijae RohP Andrew Futreal
Apr 20, 2017·PloS One·Richard LinedaleGraham R Leggatt
Oct 2, 2017·Journal of the American Academy of Dermatology·William N WilliamEdward S Kim
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Feb 9, 2018·Journal of Cutaneous Pathology·Aristea StravodimouEleni P Kourea
Mar 27, 2018·Cancer·Kathryn A GoldBonnie S Glisson
Jun 5, 2018·The New England Journal of Medicine·Michael R MigdenMatthew G Fury
Jul 14, 2018·Frontiers in Immunology·Kristina Buder-Bakhaya, Jessica C Hassel
Apr 21, 2019·Cancer Immunology Research·Aaron M GoodmanRazelle Kurzrock